File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Who should be treated for Helicobacter pylori infection?

TitleWho should be treated for Helicobacter pylori infection?
Authors
KeywordsDyspepsia/drug therapy
Helicobacter infections/therapy
Helicobacter pylori
Peptic ulcer/drug therapy
Stomach neoplasms
Issue Date1999
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org.hk
Citation
Hong Kong Medical Journal, 1999, v. 5 n. 2, p. 151-157 How to Cite?
AbstractHelicobacter pylori infection affects approximately half of the worldԸ?s population. In Hong Kong, approximately 55% of the population is infected with this organism. But symptoms and clinical disease develop in only a minority of infected individuals during their lifetime. Treatment should thus be appropriately targeted. It is imperative that infected patients who have either a current or past history of peptic ulcer disease, with or without bleeding or a perforation complication, and those with low-grade gastric, mucosal-associated lymphoid tissue lymphoma should all have the organism eliminated. There is evidence that antiԸ?Helicobacter pylori therapy reduces the recurrence of gastric cancer after the successful removal of early gastric cancer lesions. Patients with non-ulcer dyspepsia, particularly those with severe symptoms, should also be considered for a trial of eradication therapy. Whether or not eradication therapy should be given to those who require long-term non-steroidal anti-inflammatory drug therapy, but who do not have a history of peptic ulcer disease is still not decided. The use of prophylactic eradication to stop the development of gastric cancer or peptic ulceration in H pylori--positive but asymptomatic individuals should be considered only in research settings.
Persistent Identifierhttp://hdl.handle.net/10722/45094
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorChing, CKen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2007-10-30T06:17:18Z-
dc.date.available2007-10-30T06:17:18Z-
dc.date.issued1999en_HK
dc.identifier.citationHong Kong Medical Journal, 1999, v. 5 n. 2, p. 151-157en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/45094-
dc.description.abstractHelicobacter pylori infection affects approximately half of the worldԸ?s population. In Hong Kong, approximately 55% of the population is infected with this organism. But symptoms and clinical disease develop in only a minority of infected individuals during their lifetime. Treatment should thus be appropriately targeted. It is imperative that infected patients who have either a current or past history of peptic ulcer disease, with or without bleeding or a perforation complication, and those with low-grade gastric, mucosal-associated lymphoid tissue lymphoma should all have the organism eliminated. There is evidence that antiԸ?Helicobacter pylori therapy reduces the recurrence of gastric cancer after the successful removal of early gastric cancer lesions. Patients with non-ulcer dyspepsia, particularly those with severe symptoms, should also be considered for a trial of eradication therapy. Whether or not eradication therapy should be given to those who require long-term non-steroidal anti-inflammatory drug therapy, but who do not have a history of peptic ulcer disease is still not decided. The use of prophylactic eradication to stop the development of gastric cancer or peptic ulceration in H pylori--positive but asymptomatic individuals should be considered only in research settings.en_HK
dc.format.extent50405 bytes-
dc.format.extent125545 bytes-
dc.format.extent9342 bytes-
dc.format.extent2152 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org.hken_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectDyspepsia/drug therapyen_HK
dc.subjectHelicobacter infections/therapyen_HK
dc.subjectHelicobacter pylorien_HK
dc.subjectPeptic ulcer/drug therapyen_HK
dc.subjectStomach neoplasmsen_HK
dc.titleWho should be treated for Helicobacter pylori infection?en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=5&issue=2&spage=151&epage=157&date=1999&atitle=Who+should+be+treated+for+Helicobacter+pylori+infection?en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid11821584en_HK
dc.identifier.hkuros50510-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats